Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest Financial Results

Q2 2021

Quarter Ended Jun 30, 2021

Stock Information

Company Overview

Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. Acurx's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin- Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

Download DNA polymerase IIIC Inhibitor ibezapolstat, first of a new class of antibiotics with a novel mechanism of action: Clinical Trial Update

Leadership

Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information

Company

Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, NY 10305

Investor Relations

In-Site Communications
Lisa Wilson